Sequoia Financial Advisors LLC Has $362,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Sequoia Financial Advisors LLC lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 79.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,962 shares of the medical research company’s stock after selling 7,569 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Charles River Laboratories International were worth $362,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. raised its position in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Tortoise Investment Management LLC lifted its stake in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth $56,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Barclays cut their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $191.31.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James C. Foster bought 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $177.02 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.05 billion, a P/E ratio of 1,180.13, a PEG ratio of 4.54 and a beta of 1.45. The company’s 50-day simple moving average is $167.21 and its 200 day simple moving average is $184.18.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).